中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2010年
6期
631-632
,共2页
弥凝%中枢性尿崩症%垂体腺瘤%经垛手术
瀰凝%中樞性尿崩癥%垂體腺瘤%經垛手術
미응%중추성뇨붕증%수체선류%경타수술
Minirin%Central diabetes insipidus%Pituitary adenoma%Transsphenoidal surgery
目的 观察口服弥凝片治疗经蝶垂体腺瘸术后中枢性尿崩症的疗效.方法 观察经蝶垂体腺瘤术后中枢性尿崩症患者口服弥凝片(0.1 mg,3次/d)2用前、后的尿量、尿渗透压等指标的变化.结果 34例患者口服弥凝前尿量为(7985.40±410.36)ml/d,血渗透压为(301.68±3.59))mOsm/kg;口服弥凝2周后,尿量较前减少至(2277.87±328.94)ml/d;血渗透压上升达(313.26±4.87)mOsm/kg,差异均有统计学意义(P均<0.01).用药期间无一例有不良反应.结论 口服弥凝片治疗经蝶垂体腺瘤术后尿崩症疗效明确,安全、方便.
目的 觀察口服瀰凝片治療經蝶垂體腺瘸術後中樞性尿崩癥的療效.方法 觀察經蝶垂體腺瘤術後中樞性尿崩癥患者口服瀰凝片(0.1 mg,3次/d)2用前、後的尿量、尿滲透壓等指標的變化.結果 34例患者口服瀰凝前尿量為(7985.40±410.36)ml/d,血滲透壓為(301.68±3.59))mOsm/kg;口服瀰凝2週後,尿量較前減少至(2277.87±328.94)ml/d;血滲透壓上升達(313.26±4.87)mOsm/kg,差異均有統計學意義(P均<0.01).用藥期間無一例有不良反應.結論 口服瀰凝片治療經蝶垂體腺瘤術後尿崩癥療效明確,安全、方便.
목적 관찰구복미응편치료경접수체선가술후중추성뇨붕증적료효.방법 관찰경접수체선류술후중추성뇨붕증환자구복미응편(0.1 mg,3차/d)2용전、후적뇨량、뇨삼투압등지표적변화.결과 34례환자구복미응전뇨량위(7985.40±410.36)ml/d,혈삼투압위(301.68±3.59))mOsm/kg;구복미응2주후,뇨량교전감소지(2277.87±328.94)ml/d;혈삼투압상승체(313.26±4.87)mOsm/kg,차이균유통계학의의(P균<0.01).용약기간무일례유불량반응.결론 구복미응편치료경접수체선류술후뇨붕증료효명학,안전、방편.
Objective To observe the effect of oral minirin in postoperative transsphenoidal surgery patients with central diabetes insipidus. Methods The changes in the urine volume and osomlality after two weeks of minirin medication (0. lmg, 3 times each day) were observed in 34 patients with central diabetes insipidus underwent transsphenoidal surgery. Results After two weeks of minirin therapy,the average daily urine volume decreased from 7985.40 ±410. 36 ml to 2277. 87 ± 328. 94 ml,and the average plasmas osmolarity increased from 301. 68 ± 3. 59 ml/d to 313. 26 ±4. 87 mOsm/ kg. No adverse reaction was observed during the therapy. Conclusions Minirin is effective and safe in the therapy of postoperative transsphenoidal surgery patients with central diabetes insipidus.
